Neo-sagittasine A
Neo-sagittasine A (compound 2) is an estrogen biosynthesis promoter that can enhance estrogen biosynthesis in human ovarian granulosa-like KGN cells. Neo-sagittasine A can be isolated from Epimedium brevifolium.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1804014-67-2
- Formule: C27H30O11
- Masse moléculaire:530.52
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
Chemical Information
-
CAS No. 1804014-67-2
-
Masse moléculaire 530.52
-
Formule C27H30O11
-
SMILES
C=C(C(CC1=C2OC(C3=CC=C(C=C3)OC)=C(C(C2=C(C=C1O)O)=O)O[C@@H]4O[C@H]([C@@H]([C@H]([C@H]4O)O)O)C)O)C
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)